The insulin-like growth factor pathway as a target for cancer therapy.
The insulin-like growth factor (IGF) system is emerging as a promising new target in cancer therapy. Experimental models and epidemiological studies have demonstrated that the IGF system plays a key role in malignant transformation and cancer progression. Different strategies are being pursued to target this pathway. Several monoclonal antibodies and tyrosine kinase inhibitors targeting the IGF-1 receptor are in clinical development. Early clinical trials indicate these drugs have acceptable safety profiles, and there is pharmacodynamic evidence that actual target inhibition is achievable in patients. Emerging efficacy data as single agent and in combination with chemotherapy is encouraging yet too early for firm conclusions. This manuscript reviews the role of the IGF system in human malignancy and its interactions with other signaling pathways, and summarizes the available data of IGF-1R inhibitors currently in clinical trials.
López-Calderero
Iker
I
Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS), Sevilla, Spain.
Sánchez Chávez
Elizabeth
E
García-Carbonero
Rocío
R
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002986:Clinical Trials as Topic / Q000379:methods; D016503:Drug Delivery Systems; D006801:Humans; D008954:Models, Biological; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D017526:Receptor, IGF Type 1 / Q000037:antagonists & inhibitors / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects / Q000235:genetics / Q000502:physiology; D013002:Somatomedins / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism / Q000502:physiology*
D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D013002:Somatomedins; D017526:Receptor, IGF Type 1
Annu Rev Biochem. 1992;61:307-30
1323236
Lancet Oncol. 2010 Feb;11(2):129-35
20036194
Ann Intern Med. 1995 Mar 1;122(5):327-34
7847643
Oncogene. 2005 Jul 7;24(29):4736-40
15870705
Indian J Med Res. 2007 Apr;125(4):511-22
17598937
N Engl J Med. 2004 Oct 14;351(16):1619-26
15483280
Proc Natl Acad Sci U S A. 2001 Jun 19;98(13):7200-5
11404460
Clin Cancer Res. 2007 Feb 15;13(4):1198-207
17317830
Cancer Res. 2003 Aug 1;63(15):4384-8
12907608
Clin Transl Oncol. 2009 Sep;11(9):572-9
19775996
Cancer Res. 2006 Oct 15;66(20):10100-11
17047074
J Clin Oncol. 2009 Dec 1;27(34):5800-7
19786654
Cancer Res. 2005 Dec 1;65(23):11118-28
16322262
Endocr Rev. 2001 Dec;22(6):800-17
11739334
Cancer Res. 1972 Feb;32(2):226-32
5058183
J Clin Oncol. 2008 Jul 1;26(19):3196-203
18474873
Cancer Res. 2005 Mar 15;65(6):2085-8
15781617
J Biol Chem. 2001 Oct 26;276(43):40080-6
11457860
J Natl Cancer Inst. 1999 Apr 7;91(7):620-5
10203281
BJU Int. 2008 Feb;101(4):436-9
18234062
Nat Clin Pract Oncol. 2007 Oct;4(10):591-602
17898809
Nature. 2006 May 25;441(7092):424-30
16724053
Oncogene. 2000 Feb 17;19(7):889-98
10702797
Mod Pathol. 2006 Jun;19(6):788-96
16575403
Science. 1998 Jan 23;279(5350):563-6
9438850
Mol Cancer Res. 2003 Feb;1(4):312-22
12612059
Cancer Res. 2005 May 1;65(9):3781-7
15867374
Endocr Relat Cancer. 2005 Dec;12(4):1017-36
16322340
Eur J Cancer. 1993;29A(16):2256-64
8110496
Biochem Biophys Res Commun. 2006 Apr 14;342(3):851-8
16499871
Arch Physiol Biochem. 2008 Feb;114(1):23-37
18465356
Nat Rev Drug Discov. 2002 Oct;1(10):769-83
12360255
Cancer Res. 2008 Mar 1;68(5):1538-45
18316619
Endocrinology. 2004 Nov;145(11):4976-84
15271882
J Natl Cancer Inst. 2006 Jan 18;98(2):123-34
16418515
Clin Cancer Res. 2007 Oct 1;13(19):5834-40
17908976
J Clin Oncol. 2009 May 20;27(15):2516-22
19380445
J Pharmacol Exp Ther. 2006 Aug;318(2):666-75
16682453
Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):11217-21
8248231
Cancer Res. 2003 Mar 15;63(6):1166-71
12649170
Acta Physiol Hung. 2005;92(2):97-107
16268048
Proc Natl Acad Sci U S A. 2006 May 2;103(18):6901-6
16641105
Biochem J. 2007 May 1;403(3):603-13
17291192
Nature. 1995 Oct 19;377(6550):646-9
7566179
Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20926-31
18087038
Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3455-60
10737798
J Biol Chem. 2008 Feb 1;283(5):2604-13
18048361
Curr Opin Pharmacol. 2008 Aug;8(4):384-92
18674638
Clin Cancer Res. 2015 Feb 15;21(4):701-11
25212606
J Clin Oncol. 2009 Jan 10;27(2):176-85
19064975
J Clin Invest. 1963 Nov;42:1816-34
14083170
Cancer Res. 1984 Dec;44(12 Pt 1):5486-90
6093996
Curr Pharm Des. 2007;13(7):671-86
17346183
J Exp Med. 1995 Aug 1;182(2):593-7
7543144
J Cell Biochem. 2006 Oct 1;99(2):392-401
16639715
Oncogene. 2005 Aug 18;24(35):5510-20
15897888
Proc Natl Acad Sci U S A. 1976 Dec;73(12):4536-40
1070004
Clin Cancer Res. 2011 Oct 1;17(19):6304-12
21810918
Cancer Chemother Pharmacol. 2010 Mar;65(4):765-73
19649631
N Engl J Med. 2003 Apr 24;348(17):1625-38
12711737
J Biol Chem. 2001 Mar 30;276(13):9817-24
11139588
Int J Cancer. 1996 Aug 22;69(4):335-9
8797879
J Natl Cancer Inst. 2001 Dec 19;93(24):1852-7
11752009
J Clin Oncol. 2006 May 1;24(13):1982-9
16648498
Mol Cell Biol. 2006 Mar;26(5):1754-69
16478996